Sanofi to Invest USD 75 million in a New Manufacturing Facility in Vietnam

PR Newswire/Les Echos/ 
PRESS RELEASE 
Sanofi to Invest USD 75 million in a New Manufacturing Facility in Vietnam 
Paris, France - March, 29, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) 
announces today the official launch of a construction project for a new 
manufacturing facility in the Saigon High Tech Park - Ho Chi Minh City, during 
a ceremony in the presence of Christopher A. Viehbacher, Chief Executive 
Officer of Sanofi. The new state-of-the-art plant will expand Sanofi's 
manufacturing capacity in Vietnam to meet the fast growing demand of the 
Vietnamese pharmaceutical market and will serve as an export platform to 
ASEAN(*) countries. 
The investment in this new plant will amount to USD 75 million and will
constitute Sanofi's largest investment in Vietnam to date. With an initial
capacity of 90 million units per year - and a possible extension up to 150
million units - the facility will produce high-quality pharmaceuticals and
consumer healthcare products. The plant is scheduled to be fully operational 
by the end of 2015 and will join Sanofi's existing network of 40 manufacturing
sites in Emerging Markets. 
"This new production and development center is the largest investment ever made
by Sanofi in Vietnam and illustrates our commitment to bringing high quality
medicines to a broader population in Vietnam", said Christopher A. Viehbacher,
Chief Executive Officer of Sanofi. "Sanofi has been present in Vietnam for more
than 50 years and has built the number 1 position in one of the most dynamic
South East Asian countries. This new investment will contribute to further
strengthen Sanofi's leadership position in Emerging Markets". 
(*) ASEAN: Association of South East Asian Nations 
About Sanofi in Vietnam
Sanofi Vietnam head office is located in Ho Chi Minh City. Its products have
been present in Vietnam for more than 50 years. The company currently has about
1,200 employees working nationwide. Sanofi is the only foreign pharmaceutical
company with two WHO-GMP certified manufacturing facilities in Ho Chi Minh 
City, manufacturing 80% of the volume of Sanofi products marketed in Vietnam. 
The long history, wide product portfolio, and leading position in the country 
give Sanofi a unique expertise to answer the patients' needs in Vietnam. Sanofi
has established a strong partnership with Vinapharm since 1993. In 2012, Sanofi
Vietnam is the market leader with a market share of 4%. For more detail
information, please visit website: www.sanofi.com.vn  
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris 
(EURONEXT: SAN) and in New York (NYSE: SNY). For more information, please visit
website: www.sanofi.com  
Sanofi Forward Looking Statements
This press release contains forward-looking statements as defined in the 
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking 
statements are statements that are not historical facts. These statements 
include projections and estimates and their underlying assumptions, statements 
regarding plans, objectives, intentions and expectations with respect to future
financial results, events, operations, services, product development and 
potential, and statements regarding future performance. Forward-looking 
statements are generally identified by the words "expects", "anticipates", 
"believes", "intends", "estimates", "plans" and similar expressions. Although 
Sanofi's management believes that the expectations reflected in such 
forward-looking statements are reasonable, investors are cautioned that 
forward-looking information and statements are subject to various risks and 
uncertainties, many of which are difficult to predict and generally beyond the 
control of Sanofi, that could cause actual results and developments to differ 
materially from those expressed in, or implied or projected by, the 
forward-looking information and statements. These risks and uncertainties 
include among other things, the uncertainties inherent in research and 
development, future clinical data and analysis, including post marketing, 
decisions by regulatory authorities, such as the FDA or the EMA, regarding 
whether and when to approve any drug, device or biological application that may
be filed for any such product candidates as well as their decisions regarding 
labelling and other matters that could affect the availability or commercial 
potential of such product candidates, the absence of guarantee that the product
candidates if approved will be commercially successful, the future approval and
commercial success of therapeutic alternatives, the Group's ability to benefit 
from external growth opportunities, trends in exchange rates and prevailing 
interest rates, the impact of cost containment policies and subsequent changes 
thereto, the average number of shares outstanding as well as those discussed or
identified in the public filings with the SEC and the AMF made by Sanofi, 
including those listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year
ended December 31, 2012. Other than as required by applicable law, Sanofi does 
not undertake any obligation to update or revise any forward-looking 
information or statements. 
Relations Presse                 Relations Investisseurs
Jean-Marc Podvin                 Sébastien Martel
Tél. : +33 (0) 1 53 77 46 46     Tél. : +33 (0) 1 53 77 45 45
E-mail : mr@sanofi.com           E-mail : ir@sanofi.com 
                  
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Mar/29/2013 08:54 GMT